MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases Initial Phase 1 clinical results, including biomarker data to demonstrate pharmacodynamic effects, anticipated in Q1 2025 BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, tod ...

About Monte Rosa Poster presentation today at 14:45 CET / 8:45 a.m. ET Summary of findings: The poster, entitled "MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model" (Poster Number 1200), will be presented today by Adam Cartwright, Ph.D., Senior Scientist II at Monte Rosa Therapeutics, at 14:45 CET / 8:45 a.m. ET. Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initi ...

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes in a colitis model Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with Phase 1 clinical data expected in Q1 2025 Poster presentation today at 12:30 pm ET BOSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical- stage biotechnology company ...

Marti Technologies, Inc. (NYSE:MRT) Q4 2023 Earnings Call Transcript April 16, 2024 8:30 AM ET Company Participants Oguz Alper Oktem - Founder and CEO Cankut Durgun - Co-Founder and President Conference Call Participants Thomas Shemia - Cantor Fitzgerald Operator Hello, everyone, and thank you for joining us for Marti's Full Year 2023 Conference Call. Before we begin, I would like to mention that today's presentation and earnings release are available on Marti's investor relations website at ir.marti.tech, ...

If our assumptions regarding these risks and uncertainties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks successfully, our results of operations could differ materially from our expectations and our business, financial condition, and results of operations could be adversely affected. The size of our rider base is critical to our success. Our financial performance has been and will continue to be significantly determined by our success in cost-ef ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Galata Acquisition Corp. | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Cayman Islands | 001-40588 | N/A | | (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the period ended December 31, 2022 Commission File Number 001-40588 GALATA ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 98-1704340 (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identification No.) 2001 S Street SW, Suite 320 Washington, DC 20009 (Address of pr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Galata Acquisition Corp. | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Cayman Islands | 001-40588 | N/A | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | | | | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Cayman Islands | 001-40588 | N/A | | (State or other jurisdic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 For the transition period from to Galata Acquisition Corp. | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Cayman Islands | 001-40588 | N/A | | (State or other jurisdiction of | (Commission File | (I.R.S. Employer | | incorporation or orga ...